anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Non-uniformly porous hair is uniformly waved with a cold hair waving composition by pretreating the hair with a preneutralizing agent capable, through chemical actions of partially arresting the action of the hair waving composition and subsequently treating it with the cold hair waving composition.  The nonuniformly porous hair may have been produced by previously bleaching hair with a composition comprising for example oleic acid, the glycol ether of p.ter octylphenol, octylphenoxy polyethoxyethanol, ammonia, isopropanol, propylene glycol, aqueous hydrogen peroxide, ammonium and potassium persulphates, and sodium silicate and carbonate, or by previously tinting with an oxidation dye composition comprising p-phenylenediamine, 1,5-dihydroxy-naphthalene, p-aminodiphenylamine and aqueous hydrogen peroxide.  The preneutralizing agent may act (a) by changing the pH to the acid side, (b) by oxidation of the active component of the waving composition, or (c) by a combination of (a) and (b) and may be hydrogen peroxide or alkali metal perborate or chlorite, urea peroxide, ammonium or potassium persulphate or sodium or potassium bromate.  The pre-neutralizing agent may also contain wetting agents, thickeners, opacifiers, perfume oils, preservatives, stabilizers, film formers and hair conditions.  The waving composition is preferably a solution of thioglycollic acid or its derivatives, e.g. amides and esters, having a pH of 7-9.4 and may contain alkali, e.g. ammonia, alkali or alkaline earth metal cations, ethylamine, diethylamine, triethylamine, monoethanolamine, diisoprapanolamine, triethanolamine or morpholine, opacifiers, emulsifiers, perfumes, thickening agents, film formers and hair conditions.  After treatment with the hair waving composition the hair may be treated with a neutralizing agent.
Death is a multifaceted process wherein each individual cell and tissue has a metabolic homeostasis and a time of functional cessation defined by the dying process as well as by intrinsic and extrinsic factors. Decomposition is physiologically associated with the release of different types of volatile organic compounds (VOCs), and these form volaboloma mortis. The main purpose of this study was to record the volabolomic fingerprint produced by volatile molecules during the physiological decomposition process of human tissue and muscle cells. The volatile chemical signature has important implications for an open issue in forensics and pathology, namely the estimation of the postmortem interval (PMI), which decreases in accuracy with the passage of time. Volatile metabolites emitted from human tissues and muscle cells at 0, 24, 48, and 72 h were recorded in real time with an electronic nose sensor device. The key findings were the continuous sampling of VOCs emitted from tissues and cells. These showed a common behavior as time progressed; particularly, after 48 h the distributions became dispersed, and after 72 h they became more variable. Volabolomic fingerprinting associated with time progression relevant to the study of PMIs was reconstructed. Additionally, there may be broader applications, such as in dog training procedures for detecting human remains, and perhaps even for studying scavenger and insect attractants.
One million patients present to US emergency departments (ED) annually for treatment of acute migraine headache. A variety of parenteral medications are used to treat acute migraine, but none offer rapid and complete headache relief without side effects. Preliminary studies have suggested that intravenous valproate, an anti-epileptic medication with established efficacy as a migraine preventive, may be useful for the treatment of acute migraine. We propose a randomized, comparative efficacy trial in which intravenous valproate is compared to two standard parenteral therapies for acute migraine. There will not be a placebo control. Included subjects will be adults 64 years and younger who meet International Headache Society criteria for acute migraine, who do not have clinical evidence of secondary (organic) headache, and who do not have allergy or contra-indication to the investigational medications. The investigational medications are 1gm of valproate, 10mg of metoclopramide, and 30mg of ketorolac. Patients will be approached for participation and randomized at the time of presentation to the ED. Pain will be assessed on an 11 point (0 to 10) verbal pain scale, validated for use in acute pain trials. Medication will be infused as a slow intravenous drip. The primary outcome will be an improvement in headache intensity one hour after initiation of the intravenous drip. Secondary outcomes include assessments of pain, functional disability, adverse events, and satisfaction with the investigational medication one, two and 24 hours after initiation of the intravenous drip. The primary analysis will use a Student's t-test for independent samples and involve three pair-wise comparisons. Using an alpha of .017 (to account for the three pairwise comparisons), a standard beta, and a validated minimum clinically significant difference on the verbal pain scale, we calculated the need for 330 subjects. An interim analysis will be conducted to determine lack of efficacy of valproate.
Intraoperative steroids were administered during transplantation and Basiliximab was administered on Day 0 and 4 (10 mg if the body weight was \<35 kg; 20 mg if body weight was ≥35 kg) in combination with cyclosporine/cyclosporine microemulsion and steroids. Basiliximab was administered as an intravenous bolus injection within 8 hours after reperfusion of the graft.
Drought is a major environmental stress that limits plant growth, so it's important to identify drought-responsive genes to understand the mechanism of drought response and breed drought-tolerant roses. Protein phosphatase 2C (PP2C) plays a crucial role in plant abiotic stress response. In this study, we identified 412 putative PP2Cs from six Rosaceae species. These genes were divided into twelve clades, with clade A containing the largest number of PP2Cs (14.1%). Clade A PP2Cs are known for their important role in ABA-mediated drought stress response; therefore, the analysis focused on these specific genes. Conserved motif analysis revealed that clade A PP2Cs in these six Rosaceae species shared conserved C-terminal catalytic domains. Collinearity analysis indicated that segmental duplication events played a significant role in the evolution of clade A PP2Cs in Rosaceae. Analysis of the expression of 11 clade A RcPP2Cs showed that approximately 60% of these genes responded to drought, high temperature, and salt stress. Among them, RcPP2C24 exhibited the highest responsiveness to both drought and ABA. Furthermore, overexpression of RcPP2C24 significantly reduced drought tolerance in transgenic tobacco by increasing stomatal aperture after exposure to drought stress. The transient overexpression of RcPP2C24 weakened the dehydration tolerance of rose petal discs, while its silencing increased their dehydration tolerance. In summary, our study identified PP2Cs in six Rosaceae species and highlighted the negative role of RcPP2C24 on rose's drought tolerance by inhibiting stomatal closure. Our findings provide valuable insights into understanding the mechanism behind rose's response to drought.
Daily treatment with any acid-suppressing medications over a long period of time (e.g., longer than 3 years) may lead to malabsorption of cyanocobalamin (vitamin B-12) caused by hypo- or achlorhydria. Rare reports of cyanocobalamin deficiency occurring with acidsuppressing therapy have been reported in the literature. This diagnosis should be considered if clinical symptoms consistent with cyanocobalamin deficiency are observed. Daily treatment with any acid-suppressing medications over a long period of time (e.g., longer than 3 years) may lead to malabsorption of cyanocobalamin (vitamin B-12) caused by hypo- or achlorhydria. Rare reports of cyanocobalamin deficiency occurring with acidsuppressing therapy have been reported in the literature. This diagnosis should be considered if clinical symptoms consistent with cyanocobalamin deficiency are observed.
BGM group participants will be asked to use a study blood glucose meter with test strips for a fingerstick blood glucose check with a recommendation of 4 times a day. Participants will be permitted to check a fingerstick glucose as many times a day as they choose. Participants will have a phone visits at 10 days and clinic visits at 4 weeks, 8 weeks, 16 weeks, and 26 weeks. In addition to the in-clinic study visits, the BGM group will have blinded sensor placement visits one week prior to each of the 8, 16, and 26 week visits.
The leaves of the khat tree are traditionally chewed in some African and Arab countries. They contain the mild central stimulant cathinone. In recent years, the production, trade and use has dramatically increased and excessive patterns of use as well as a specific dependence syndrome have been described. So far, no experiences exist in psychological treatment of khat addiction.

In this study, we use a brief motivational intervention based on the WHO's ASSIST-linked Brief Intervention and Motivational Interviewing to support users who have the intention to reduce or stop their khat use. Khat users will be recruited in the community. Trained local staff will assess participant's khat and other substance use at study entry and one month later. Users will be assigned randomly to intervention or waiting list control groups. The intervention group will receive a single 20-minute brief intervention. The waiting list will receive the same intervention after the second assessment. After two months, a final assessment will be made in both groups.
The invention relates to a polypeptide capable of binding to human CD38, which comprises 3 complementarity determining regions CDR1-3, wherein the sequence of CDR1 is or comprises one of the sequences shown in SEQ ID NO. 1-36, the sequence of CDR2 is or comprises one of the sequences shown in SEQ ID NO. 37-72, and the sequence of CDR3 is or comprises one of the sequences shown in SEQ ID NO. 73-111. The invention carries out nano antibody drug development and diagnostic reagent development aiming at hematopoietic system malignant tumor, and selects the nano antibody VHH specifically combined with CD38 by preparing CD38 protein, immune alpaca, platform technology for displaying nano monoclonal antibody by using phage library, etc., identifies the CDR sequence thereof, and constructs humanized antibody C38 NB; and the efficacy of C38NB in treating multiple myeloma is evaluated in vivo by using a humanized mouse model. The invention provides a potential new nano-antibody medicament and a new cell therapy medicament for clinical treatment of malignant tumors of the hematopoietic system, and provides a corresponding detection reagent for diagnosis of malignant tumors of the hematopoietic system.
INTRODUCTION: The effect of individual non-narcotic analgesics in cystectomy enhanced recovery after surgery (ERAS) is unknown. Additionally, many non-narcotic medications are associated with side effects pertinent to the cystectomy population. To better understand the actual use and utility of these medications, we sought to characterize the association between non-narcotic medications and milligram morphine equivalent (MME) narcotic score during the postoperative inpatient stay.
METHODS: We reviewed 260 consecutive ERAS cystectomy patients. The MME impact of non-narcotic compliance and cumulative dose of medication received was evaluated separately with general linear models. We also assessed relationship of non-narcotic compliance to patient reported pain score, length of stay (LOS), and time to return of bowel function (ROBF) and performed manual review of postoperative documentation to identify reasons for medication noncompliance.
RESULTS: Compliance with postoperative acetaminophen, gabapentin, and ketorolac was low. There was an inverse relationship between ketorolac dose and MME on postoperative day 1 (-0.026 MME/mg; P = 0.004) and postoperative day 2 (-0.33 MME/mg; P < 0.001). Compliance with ketorolac was associated with lower MME on postoperative day 1 (26.1 MME v. 33.6 MME; P = 0.023). There were no such associations identified with gabapentin or acetaminophen. Gabapentin compliance was associated with earlier ROBF (3.7 days v. 4.3 days; P = 0.006). Ketorolac compliance was associated with lower pain score on POD1 (3.25 VAS v. 4.07 VAS; P = 0.019) and POD2 (3.05 VAS v. 3.85 VAS; P = 0.040) There was no association between medication compliance and LOS. The most common reasons identified for non-compliance with gabapentin and ketorolac were renal function concerns (38% and 40% respectively), bleeding concerns with ketorolac (20%) and concerns for neurologic adverse effect with gabapentin (16%).
CONCLUSION: Compliance with non-narcotic medications in our ERAS cystectomy protocol was poor. There was a modest association with ketorolac and postoperative MME but no association with gabapentin or acetaminophen. Further study will clarify the role of these medications for cystectomy patients. Component specific analysis of protocolized care is valuable and may alter care pathways.
PURPOSE:To produce liposome stably with high drug inclusion and in high reproducibility by adding a small amount of volatile organic solvent to a liquid medicine containing dispersed liposome, then evaporating the organic solvent from the product. CONSTITUTION:A small amount of a volativle organic solvent, preferably diethyl ether or actone is added to a liquid medicine containing dispersed liposome, such as MLV or SUV liposome to form a gel. Then, the organic solvent is evaporated under reduced pressure or in a nitrogen gas atmosphere to give stabilized liposome with high drug inclusion in high reproducibility regardless of the production scale either limited, or in mess. The amount of the volatile organic solvent is about 1-30 pts.vol. preferably 3 5to 10 pts.vol. 10 pts.vol. of the liquid medicine. The medicine is preferably hydrophilic one, e.g., lymphokine or actinomycin.
<P>PROBLEM TO BE SOLVED: To obtain a hyaluronidase inhibitor derived from hyaluronic acid contributing to moisture retention of the skin etc., and a wrinkle formation inhibitor containing the inhibitor.  <P>SOLUTION: The hyaluronidase inhibitor includes a phosphorylcholine group-containing hyaluronic acid derivative. There may be a case in which the phosphorylcholine group-containing hyaluronic acid derivative is phosphorylcholinehyaluronic acid. The derivative maintains moisture retaining property being a main function of hyaluronic acid and has increased hydrophilicity and biocompatibility by introduction of phosphorylcholine group and ability of inhibiting hyaluronidase activity to decompose hyaluronic acid. The wrinkle formation inhibitor includes the hyaluronidase inhibitor.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The patient was a male infant, born full-term, admitted to the hospital at 28 days of age due to jaundice for 20 days and abdominal distension for 15 days. The patient developed symptoms of jaundice, hepatosplenomegaly, massive ascites, and progressively worsening liver function leading to liver failure, severe coagulation disorders, and thrombocytopenia one week after birth. Various treatments were administered, including anti-infection therapy, fluid restriction, use of diuretics, use of hepatoprotective and choleretic agents, intermittent paracentesis, blood exchange, and intravenous immunoglobulin, albumin, and plasma transfusions. However, the patient's condition did not improve, and on the 24th day of hospitalization, the family decided to discontinue treatment and provide palliative care. Sequencing of the patient's liver tissue and parental blood samples using whole-exome sequencing did not identify any pathogenic variants that could explain the liver failure. However, postmortem liver tissue pathology suggested congenital hepatic fibrosis (CHF). Given the rarity of CHF causing neonatal liver failure, further studies on the prognosis and pathogenic genes of CHF cases are needed in the future. This article provides a comprehensive description of the differential diagnosis of neonatal liver failure and introduces a multidisciplinary diagnostic and therapeutic approach to neonatal liver failure.
The Painful stiff shoulder (PSS), or the adhesive capsulitis, involves stiff and contracted joint capsule from fibrosis in the glenohumeral joint. Intra-articular hydraulic distension (IHD) enlarges the stiffened capsule by deforming it with excessive volume and pressure within the joint space. Although IHD is one of the most common treatment options for the PSS, the diversity of the IHD technique spans wide range. Specifically, it is not generally agreed as for which, between capsule-rupturing and capsule-preserving IHDs, is superior for PSS treatment. Capsule-preserving IHD might fail to infuse sufficient amount of fluid to avoid rupture, thus producing less satisfactory outcomes. However, we devised in our previous study a novel technique that enabled a physician to infuse the possible largest volume without rupturing the capsule. By employing the technique, we aim to compare the clinical efficacy of capsule-rupturing versus capsule-preserving IHDs in patients with PSSs.
HMPV is a viral respiratory pathogen that was discovered in 2001, but studies have shown that it has been circulating in humans for at least 50 years. Older adults and adults with asthma who are infected with HMPV may be at increased risk for lower respiratory illness and hospitalization. In infants and young children, HMPV infection may cause upper or lower respiratory illness, ear infections, bronchiolitis, croup, pneumonia, and exacerbations of asthma. Children less than 2 years of age are most susceptible to severe HMPV infections, and HMPV is the second or third leading cause of viral lower respiratory illness in children. The National Institute of Allergy and Infectious Diseases (NIAID) is working to develop a live-attenuated, intranasally administered HMPV vaccine for use in infants. The purpose of this study is to evaluate the safety and immunogenicity of an HMPV vaccine.

The vaccine will be evaluated in four groups of participants: healthy adults; HMPV-seropositive children; and two groups of HMPV-seronegative infants and children, with each seronegative group receiving a different dose of the vaccine. In the adult group, participants will all receive the vaccine; in the infant and children groups, participants will be randomly assigned to receive either the vaccine or a placebo. Study researchers will review participants' study data and confirm the safety of the vaccine before enrolling the next group of participants.

This study will first enroll healthy adults. At a baseline study visit, all participants will undergo a medical history review, physical examination, nasal wash procedure, vital sign measurements, and a blood collection. They will then receive the vaccine, and they will remain in the clinic for 30 minutes for observation. Participants will record their temperature daily for 12 days. Additional study visits will occur at Days 3, 4, 5, 6, 7, 10, and 12. At each study visit, participants will undergo a medical history review, vital sign measurements, and a nasal wash procedure. A final study visit will occur on Day 28 and will also include a blood collection. The second group of participants will include seropositive children. They will receive the vaccine or a placebo vaccine and take part in the same study procedures as the adult participants. Participants' parents will receive telephone calls or e-mails from study staff on Days 1, 2, 8, 9, 11, and 13 to obtain and record medical history and temperature readings. The third and fourth groups of participants will include seronegative infants and children. Each of these two groups will receive different doses of the vaccine or placebo vaccine. They will attend study visits on Days 3, 5, 7, 10, 12, 14, 17, 19, 21, 28, and 56, and they will undergo the same study procedures as the other participants. Parents of seronegative infants and children will receive telephone calls or e-mails from study staff on Days 1, 2, 4, 6, 8, 9, 11, 13, 15, 16, 18, 20, 22 to 27, and 29.

Study staff will call all participants at Month 6 for a medical history review and follow up.
Disclosed are a traditional Chinese medicine pill realizing targeted release, and a preparation method therefor. The traditional Chinese medicine pill comprises a pill core layer, a middle powder layer and an outer coating powder layer, wherein the pill core layer is made of roasted Atractylodis macrocephalae rhizoma, Pogostemonis herba, Raphani semen and Arecae semen tostum; the middle powder layer is made of Curcumae radix, Citri reticulatae pericarpium and vinegar Cyperi rhizoma; and the outer coating powder layer is made of Paeoniae radix alba, Citri sarcodactylis fructus, Linderae radix, Aucklandiae radix, Glycyrrhizae radix et rhizome praeparata cum melle and Bupleuri radix. The content of paeoniflorin in each unit of formulation is not less than 0.66 mg, and the content of arecoline is not less than 0.07 mg. The pill is divided into inner, middle and outer layers, and according to the severity of a disease, the pill exerts a curative effect through different drug layers by means of targeted release. Symptoms are treated first, and then root causes are treated. The pill exerts effects successively and finally achieves the purpose of treating both the symptoms and the root causes, which can significantly improve the clinical efficacy.
Cancer is a challenging issue for human health. One of the key methods to address this issue is by comprehending the molecular causes of tumors and creating medications that target those causes. RBX2 (RING box protein 2), also known as ROC2 (Regulator of Cullins 2), RNF7 (RING Finger Protein 7), or SAG (Sensitive to Apoptosis Gene) is a key component of the Cullin-RING-type E3 ubiquitin ligases (CRLs) and overexpressed in various human cancers. RBX2 is a potential drug target, the expression of which correlates with tumor staging, grading, and prognosis analysis. Through a synergistically biological interaction with Kras mutation in preclinical models, RBX2 accelerated the progression of skin cancer, pancreatic cancer, and lung cancer. In accordance, the aberrant expression of RBX2 will lead to dysregulation of many signaling pathways, which is crucial for tumor initiation and growth. However, the impact of RBX2 on tumors also intriguingly demonstrates a spatial reliance manner. In this review, we summarized the current understanding of RBX2 in multiple cancer types and suggested a significant potential of RBX2 as a therapeutic target.
Non interventional trial: male or female children with a definite diagnosis of TSC (Roach 1998), aged up to 4 years, diagnosis of epilepsy established on the basis of clinical seizures or epileptiform changes on EEG within 1-7 days prior to baseline. We plan to enroll 60 TSC patients into WP1 to Epimarker in 12 months.